RxDoctor Payments Data

Tony Nimeh, MD

Urology · Fairbanks, AKNPI 1760804777

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (48.6%), travel and lodging and education — rather than concentrated in one kind of arrangement. Neotract Inc. accounts for 65.1% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $2,918 and has fallen 94.8% since, to $151 in 2024.

$4,419in general payments, 2019–2025

Across 75 payments — averaging $58.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neotract Inc.$3K
  • Astellas Pharma US Inc$247
  • Teleflex LLC$246
  • Johnson & Johnson$148
  • Boston Scientific$137
  • Endo Pharmaceuticals Inc.$137
  • plus $625 from 15 others

What the payments were for

  • Travel & lodging$2,14449%
  • Food & beverage$2,14949%
  • Education$1263%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,419 in reported general payments places this provider in the 80th percentile of 28 urology providers in Alaska.

See all urology providers in Alaska

Medicare billing

Part B allowed, 2024
$163,583
Medicare patients
246
Services billed
2,071

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron15$15,540
GemtesaVibegron11$14,792
Tamsulosin Hcl240$4,731
Solifenacin Succinate45$1,962
Finasteride92$1,527
Oxybutynin Chloride ErOxybutynin Chloride12$464
Levofloxacin27$51
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen13$21

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$247$15,54015 claims
Sumitomo Pharma America, Inc.Gemtesa$21$14,79211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 28 urology providers in Alaska.

Other urology in Fairbanks

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →